NeoGenomics price target raised to $20 from $18 at Piper Sandler

Piper Sandler analyst David Westenberg raised the firm’s price target on NeoGenomics to $20 from $18 and keeps an Overweight rating on the shares. The analyst updated estimates post the earnings report.